To persuade a mission-driven organization to embrace radical change, leaders must first clearly articulate what will remain constant. By anchoring the transformation to the enduring mission of "original, independent, reported journalism," it gives employees the emotional buy-in to join the journey.

When Tubulus pivoted its lead program from liquid to solid tumors, the team's ability to change direction instantly stemmed directly from the company's foundational culture of trust. Openly explaining the rationale behind major strategic decisions allows employees to follow and execute without friction, even on a dime.

When pivoting, trying to bring everyone along creates drag. The more effective strategy is to treat the change like an insurgency: identify believers, add weight to their efforts, and help them succeed. Their momentum becomes the charismatic force that aligns the rest of the company, pulling people along rather than pushing them.

To humanize R&D and maintain motivation, biotech leaders bring patients into the company. This practice directly connects scientists with the human impact of their work, grounding the entire team in their shared purpose, especially on difficult days.

A biotech transitioning from a small, 'fit-for-purpose' R&D team to a large commercial organization gets a rare chance to create a new culture. Madrigal treated its rapid growth from ~100 to over 500 people as an opportunity to establish fresh core values for the newly-formed enterprise.

Artiva's rapid pivot wasn't just opportunistic. It was enabled by a critical moment where the company faced an "uphill battle" and "existential questions" about its future in crowded oncology. The emergence of a new, de-risked path in autoimmune disease provided a compelling alternative at the exact moment the team was most receptive to change.

To provide a North Star for her organization, Lara Balazs championed a new mission: "empowering everyone to create." Though changing a mission is risky, it connected the brand's legacy to its future. This served as a powerful tool to motivate her team and align the entire company, proving a mission's value as an internal driver.

Hazel's founder frames their major business model change not as a failure, but as finding a better path to the same goal. Their mission was always to increase competition in government procurement. This missionary focus provided the stability and clarity needed to make a difficult but correct product pivot.

While acknowledging that repurposing a failed drug feels like a "leap of faith," Declan Doogan stresses it's not a blind gamble. The successful pivot at Amarin was based on a "thorough and rigorous assessment of the science evidence based thinking," highlighting that radical strategic shifts must be built on a strong scientific foundation.